|Home | About | Journals | Submit | Contact Us | Français|
This lecture considers the pharmacotherapy of depression with EPA under the following headings:
• Epidemiological evidence
• Biochemical evidence
• First trial of pure EPA in severe treatment-resistant depression
• Subsequent randomized double-blind placebo-controlled trials
• Putative mechanisms.
Results obtained from our own group, including structural neuroimaging and 31-phosphorus neurospectroscopy findings, showing an association of EPA treatment of depression with a marked decrease in cerebral phosphodiesters, a marked increase in cerebral phosphomonoesters and reduced lateral ventricular volume, will also be presented.